Logo image
Back
Effect of Rosuvastatin on C-Reactive Protein and Renal Function in Patients With Chronic Kidney Disease
Journal article   Peer reviewed

Effect of Rosuvastatin on C-Reactive Protein and Renal Function in Patients With Chronic Kidney Disease

Anil Verma, Karthik M. Ranganna, Rani S. Reddy, Mandeep Verma and Neil F. Gordon
The American journal of cardiology, v 96(9), pp 1290-1292
2005
DOI: https://doi.org/10.1016/j.amjcard.2005.06.074
PMID: 16253600
Featured in Collection :   UN Sustainable Development Goals @ Drexel

Abstract

The purpose of this 20-week, open-label, randomized clinical trial was to evaluate the effect of rosuvastatin on fasting serum lipids and lipoproteins, high-sensitivity C-reactive protein (hs-CRP), and the glomerular filtration rate (GFR) in 91 patients with chronic kidney disease. Patients were randomized to rosuvastatin 10 mg/day (n = 48) or to no lipid-lowering treatment (n = 43) for 20 weeks. In contrast to patients not receiving rosuvastatin, patients receiving rosuvastatin tended to derive more favorable improvements from baseline values in low-density lipoprotein cholesterol (−43%, p <0.001, vs 7%, p = NS; p <0.001 for change with rosuvastatin treatment vs change with no antilipemic treatment), hs-CRP (−47%, p <0.001, vs 7%, p = NS; p <0.001 for change with rosuvastatin treatment vs change with no antilipemic treatment), and GFR (11%, p <0.05, vs 4%, p = NS; p = NS for change with rosuvastatin treatment vs change with no antilipemic treatment).

Metrics

4 Record Views
64 citations in Web of Science
67 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image